Avalo Therapeutics, Inc., was incorporated in Delaware on January 31, 2011. The company is a clinical-stage biotechnology company fully committed to developing IL-1β-based immune-mediated inflammatory disease treatments. The Company's lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (" MAB "), is in Phase 2 clinical trials for hidradenitis suppurativa (" HS "). The company is also exploring more opportunities to make an impact in popular indications where there is a large unmet need. 

AVTX

AVTX Profile